American Well Corp (AMWL) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. American Well Corporation is a leading enterprise software company enabling digital delivery of care. The company operates as a single reporting segment, focusing on its Converge platform, professional services, and affiliated clinical services (AMG). The company is an accelerated filer with no debt outstanding.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenue | $56.3 million | $61.0 million | $194.0 million | $183.4 million |
| Net Loss (GAAP) | $(31.9) million | $(44.0) million | $(69.8) million | $(168.1) million |
| Net Loss Attributable to AMWL | $(32.4) million | $(43.5) million | $(70.8) million | $(165.5) million |
| Adjusted EBITDA | $(12.7) million | $(31.0) million | $(29.6) million | $(111.6) million |
| Cash and Equivalents | $200.9 million | $228.3 million (Dec 2024) | $200.9 million | $228.3 million (Dec 2024) |
| Operating Cash Flow | N/A | N/A | $(48.6) million | $(113.9) million |
| Debt | $0 | $0 | $0 | $0 |
Material Changes vs. Prior Period
- Revenue: Q3 2025 revenue decreased 8% year-over-year to $56.3 million, primarily due to the divestiture of the APC (telepsychiatry) business and lower urgent care/behavioral health visit volumes. However, YTD revenue increased 6% to $194.0 million, driven by a $25.0 million increase in subscription revenue from strategic customer arrangements.
- Cost Reductions: Total costs and operating expenses decreased 21% in Q3 and 23% YTD. Significant reductions were seen in Sales and Marketing (46% decrease in Q3) and Cost of Revenue (30% decrease in Q3), driven by headcount reductions (29% in Cost of Revenue, 49% in S&M) and the sale of the APC business.
- Profitability: Operating loss improved significantly, decreasing 38% in Q3 to $(29.3) million and 54% YTD to $(80.1) million. Net loss improved 28% in Q3 and 58% YTD.
- Divestiture: The company completed the sale of the APC Business in January 2025, recognizing a net gain of $8.7 million in the nine months ended September 30, 2025.
Guidance, Outlook, and Risks
- Strategic Focus: Management is streamlining service offerings to focus resources on the Converge platform, strategic customers, and the path to profitability. The APC divestiture was executed as the offering no longer fit profitability goals.
- Outlook: The company expects R&D, Sales & Marketing, and G&A expenses to decrease in the current year and remain flat in future periods. Management believes existing cash ($200.9 million) is sufficient for at least the next 12 months.
- Key Risks:
- History of losses and risk of not achieving profitability.
- Concentration risk: Two clients accounted for 51% and 10% of accounts receivable as of September 30, 2025.
- Regulatory changes in healthcare reimbursement and digital care laws.
- Seasonality: Visit volumes typically rise in Q4 and Q1 and fall in summer months.
- Unusual Items: The company recorded $3.2 million in severance and strategic transformation costs in Q3 2025. Additionally, a $1.0 million investment was made in Aingelz, Inc. via a SAFE agreement for AI development.
Investor Verification Checklist
- Revenue Quality: Verify the sustainability of the $25 million YTD subscription revenue increase and the impact of the APC divestiture on future visit-based revenue.
- Cash Burn: Monitor the operating cash burn rate (YTD $48.6 million) against the $200.9 million cash balance to assess runway.
- Client Concentration: Assess the risk associated with the top two clients representing 61% of accounts receivable.
- Cost Structure: Confirm that the significant headcount reductions (up to 49% in S&M) are sustainable and do not impair future growth capabilities.
- Divestiture Proceeds: Track the realization of the contingent "Additional Payment" (0.4x revenues) from the APC sale, which is accounted for when realizable.